Unveiling the pan-cancer landscape of S100A16: A comprehensive analysis of prognostic significance, drug sensitivity, and immunomodulatory roles.

Autor:	Shang S; Department of Pathology, The First People's Hospital of Jiangxia District, Wuhan, China., Hu L; Department of Medical Examination, Wuhan Red Cross Hospital, Wuhan, China., Wu C; Department of Medical Laboratory, Wuhan Red Cross Hospital, Wuhan, China., Wu J; Department of Pathology, The First People's Hospital of Jiangxia District, Wuhan, China., Chen M; Department of Pathology, The First People's Hospital of Jiangxia District, Wuhan, China., Zhu G; Department of Medicine, Singlera Genomics (Shanghai) Ltd., Shanghai, China., Xu WY; Department of Medicine, Singlera Genomics (Shanghai) Ltd., Shanghai, China., Zhang Y; Department of Medicine, Singlera Genomics (Shanghai) Ltd., Shanghai, China., Sun G; Department of Medicine, Singlera Genomics (Shanghai) Ltd., Shanghai, China., Wei Z; Department of Oncology, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China.
Jazyk:	angličtina
Zdroj:	Medicine [Medicine (Baltimore)] 2024 Oct 11; Vol. 103 (41), pp. e39998.
DOI:	10.1097/MD.0000000000039998
Abstrakt:	Accumulating evidence supports the notion that S100A16 exhibits differential expression in many human cancers, affecting cellular functions associated with tumorigenesis through various signaling pathways. While extensive research has been conducted on S100A16 in specific cancer types, a comprehensive evaluation of its role across diverse cancers remains lacking. To explore the prognostic significance, drug sensitivity, and immunomodulatory roles of S100A16, a thorough analysis was conducted at a pan-cancer level using multiple databases. Our findings revealed high expression of S100A16 RNA in various human cancers. Importantly, this elevated expression was linked to disease prognosis and drug sensitivity across a spectrum of cancers. Genetic alterations in S100A16 were characterized across multiple cancer types, and a confirmed correlation was observed in the prognosis of skin cutaneous melanoma (SKCM). Furthermore, our study demonstrated a significant association between S100A16 expression and the infiltrating levels of diverse cell types in the tumor microenvironment (TME), suggesting its potential as a prognosis predictor for immunotherapy. Novel collections of miRNAs, such as has-miR-423-5p, has-miR-769-5p, has-miR-151a-3p, and has-miR-550a-5p, targeting S100A16 at a pan-cancer level were predicted through various databases. These findings contribute to a comprehensive understanding the role of S100A16 in prognosis prediction, chemotherapy, and immunotherapy, providing valuable insights for identifying novel targets in cancer treatment. Competing Interests: The authors have no funding and conflicts of interest to disclose. (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu